Blueweave
Lung Cancer Genomic Testing Medicine Market

Lung Cancer Genomic Testing Medicine Market

Lung Cancer Genomic Testing Medicine Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2018–2028, Segmented By Product Type (Products and Services); By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and others); By Sample Type (Tissue Biopsy and Liquid Biopsy); By Panel Type (Multi-Gene Panel and Single-Gene Panel); By End-User (Research Organization, Hospitals/ Clinics, Diagnostic Laboratories, and others); By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa)

  • Published Date: October 2022
  • Report ID: BWC22465
  • Available Format: PDF
  • Page: 240

Report Overview

Global lung cancer genomic testing medicine market is growing owing to rising number of cancer patients leading to recent launches of novel lung cancer genomic testing as well as expanding research into lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.

Global Lung Cancer Genomic Testing Medicine Market - Industry Trends & Forecast Report 2028

Global lung cancer genomic testing medicine market is projected to reach USD 4.27 billion by the year 2028, exhibiting a CAGR of 10.1% during 2022-2028 (forecast period). The rapid expansion of the market is predominantly due to the rise in the number of cancer patients around the world, as well as increasing awareness and adoption of the lung cancer genomic testing medicine market, recent launches of novel lung cancer genomic testing, and expanding research in the field of lung cancer, with an emphasis on pharmacogenomics and the development of companion diagnostics is also propelling the global lung cancer genomic testing medicine market.

Lung Cancer Genomic Testing Medicine Market 

Global Lung Cancer Genomic Testing Medicine Market - Overview

Lung cancer genetic testing is a relatively new industry with a limited global presence. Companies are investing more money in R&D to speed up the creation of lung cancer genomic testing, which will likely lead to more people using these tests. Lung cancer genomic testing will become more widely used as healthcare systems move toward precision diagnostics and precision medicine, allowing for more educated treatment decisions and better health outcomes. As more and more international oncology societies advocate for genomic testing in lung cancer diagnosis, the worldwide lung cancer genomic testing market is poised for significant growth.

Global Lung Cancer Genomic Testing Medicine Market Forecast and Trends

Growth Drivers

The rise in the number of cancer patients driving the market growth

During the time covered by this estimate, it is anticipated that the primary factor that will be responsible for the significant rise of the market for genomic cancer testing will be the rising incidence of breast and lung cancer. The increase in the number of cancer awareness initiatives carried out by non-governmental organizations (NGOs) helps to drive the growth of the market for genomic cancer testing. The creation of innovative cancer genomic testing procedures is currently receiving a significant amount of emphasis from major manufacturers. Another important aspect that is contributing to the expansion of the market is the rising priority placed on research and development of lung cancer diagnostic and screening tests.

Restraints

Due to a lack of awareness, the market growth is restricted

The majority of people, especially those in the lower socioeconomic groups, cannot afford screening because of its high cost. It is also anticipated that there will be a reduction in the number of screening tests carried out in developing and underdeveloped nations due to a shortage of radiologists. The implementation of lung screening technologies is hampered by the aforementioned challenges, and it is projected that this will continue to be the case in the foreseeable future.

Opportunities

Evolution of healthcare systems toward precision diagnostics and precision medicinal treatments

The implementation of lung cancer genomic testing will be required as a result of the evolution of healthcare systems toward precision diagnostics and precision medicinal treatments. It can make it simpler to come to organizational decisions regarding treatment, which in turn can improve the quality of healthcare results as a whole. Many new prospects have become available on the worldwide market as a result of the growing number of recommendations made by international oncology associations about the application of genetic testing for the investigation of lung malignancies.

Impact of COVID-19 on Global Lung Cancer Genomic Testing Medicine Market

The utility of genetic testing in diagnostic laboratories, hospitals, and clinics is the primary factor driving growth in the global market for lung cancer genomic testing. At the outset of the COVID-19 pandemic, a number of countries went into full or partial lockdown, and all elective surgical procedures and treatments in healthcare settings were halted. The COVID-19 pandemic did not have an effect on the genetic testing for lung cancer because it is considered an elective procedure. As a result, the pandemic did not have an effect on lung cancer genomic testing.

Global Lung Cancer Genomic Testing Medicine Market – By Product Type

On the basis of product type, global lung cancer genomic testing medicine market is divided into products and services. The services category of the global market for lung cancer genomic testing is predicted to grow at a faster CAGR during the forecast period. This is as a result of the simple availability, accessibility, and flexibility of laboratory developed tests (LDTs), in addition to the lower cost of LDTs as compared to the market for the product that is dominated by IVDs.

Global Lung Cancer Genomic Testing Medicine Market – By Technology

On the basis of technology, global lung cancer genomic testing medicine market is divided into polymerase chain reaction, next-generation sequencing, fluorescence in-situ hybridization, and others. It is projected that polymerase chain reaction (PCR) segment will hold a dominant position in the global market for lung cancer genetic testing by 2028. This is owing to the overall cost-effectiveness and high sensitivity of the PCR-based genomic test for detecting lung cancer mutations that cause disease. The test was designed to detect mutations that cause lung cancer.

Global Lung Cancer Genomic Testing Medicine Market - By Sample Type

On the basis of sample type, global lung cancer genomic testing medicine market is divided into tissue biopsy and liquid biopsy. It is common practice in the medical industry to collect a lung tissue biopsy for the purpose of diagnosing lung cancer; this sample is then put through genomic testing. As a result, the market is expected to be dominated by sample types that are obtained through tissue biopsies.

Global Lung Cancer Genomic Testing Medicine Market - By Panel Type

On the basis of panel type, global lung cancer genomic testing medicine market is divided into multi-gene panel and single-gene panel. It is anticipated that multi-gene panels will lead the market for genomic testing in the field of lung cancer worldwide. This is because taking lung tissue biopsies for the purpose of diagnosing lung cancer is normal medical practice, and medical personnel are experienced with the process. The lung tissue biopsies that are taken can then be used for genomic testing of lung cancer.

Global Lung Cancer Genomic Testing Medicine Market - By End-User

On the basis of end-user segmentation, global lung cancer genomic testing medicine market is divided into research organization, hospitals/clinics, diagnostic laboratories and others. It is anticipated that research organizations will hold the majority of share in the global market for lung cancer genomic testing. This is because there are a significant number of clinical research and academic organizations that use lung cancer genomic testing for the development of drugs, the development of companion diagnostics, and the enrolment of patients in clinical trials.

Global Lung Cancer Genomic Testing Medicine Market – By Region

On the basis of region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The market for genomic diagnostics of lung cancer will certainly be the most lucrative in North America. A large part of the credit for this goes to the numerous study, product, and service businesses that can be found in the US. The growth of the market is aided in other ways as well, including by the funding of research, the sponsorship of advancements in research, and the collaboration between prestigious institutions. The industry is also anticipated to expand in the Asia Pacific. Increased spending on life science research, technological advancements in DNA sequencing, and the emergence of new competitors are all contributing factors.

Competitive Landscape

Key players operating in the global lung cancer genomic testing medicine market are QIAGEN, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, CENTOGENE N.V., BGI, CeGaT GmbH, Illumina Inc., F. Hoffmann-La Roche Ltd, and other prominent players. The market leaders retain their supremacy by spending quite a lot on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Recent Development

  • In June of 2022, Tempus and Eli Lilly formed a partnership to provide free genomic testing for anyone with lung cancer.

  • In May of 2022, Roche joined forces with the Global Fund to aid developing nations in improving their access to lifesaving diagnostics.

  • Thermo Fisher Scientific's Oncomine Dx Target Test for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue received FDA approval in December 2021, making it one of 12 targeted therapies for NSCLC to receive this stamp of approval around the world.

  • Thermo Fisher Scientific's Oncomine Dx Target Test, a tissue-based NGS companion diagnostic, was approved by the FDA as CDx for five targeted NSCLC therapies in the US in September 2021. This approval was for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations.

  • Qiagen introduced the first tissue companion diagnostic approved by the FDA in May 2021 to detect the KRAS G12C mutation in NSCLC tumors, hence increasing the availability of precision medicine treatment choices for lung cancer patients.

Scope of the Report

Attributes

Details

Years Considered

Historical data – 2018–2021

Base Year – 2021

Estimated Year – 2022

Forecast – 2022–2028

Facts Covered

Revenue in USD Billion

Market Coverage

North America, Europe, Asia Pacific, Latin America, and Middle East and Africa

Product Service/Segmentation

By Product Type, By Technology, By Sample Type, By Panel Type, By End-User, By Region

Key Players

QIAGEN, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, CENTOGENE N.V., BGI, CeGaT GmbH, Illumina Inc., F. Hoffmann-La Roche Ltd, and other prominent players.

 

By Product Type

  • Products

  • Services

By Technology

  • Polymerase Chain Reaction

  • Next-Generation Sequencing

  • Fluorescence In-Situ Hybridization

  • Others

By Sample Type

  • Tissue Biopsy

  • Liquid Biopsy

By Panel Type

  • Multi-Gene Panel

  • Single-Gene Panel

By End-User

  • Research Organization

  • Hospitals/Clinics

  • Diagnostic Laboratories

  • Others

By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

  1. Research Framework
    1. Research Objective
    2. Product Type Overview
    3. Market Segmentation
  2. Executive Summary
  3. Global Lung Cancer Genomic Testing Medicine Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunity
      4. Challenges
    3. Technological Advancement/Recent Development
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Global Lung Cancer Genomic Testing Medicine Market Overview
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product Type
        1. Products
        2. Services
      2. By Technology
        1. Polymerase Chain Reaction
        2. Next-Generation Sequencing
        3. Fluorescence In-Situ Hybridization
        4. Others
      3. By Sample Type
        1. Tissue Biopsy
        2. Liquid Biopsy
      4. By Panel Type
        1. Multi-Gene Panel
        2. Single-Gene Panel
      5. By End-User
        1. Research Organization
        2. Hospitals/Clinics
        3. Diagnostic Laboratories
        4. Others
      6. By Region
        1. North America
        2. Europe
        3. Asia Pacific
        4. Latin America
        5. Middle East and Africa
  5. North America Lung Cancer Genomic Testing Medicine Market
      1. Market Size & Forecast by Value, 2018-2028
      2. By Value (USD Billion)
    1. Market Share & Forecast
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
      6. By Country
        1. US
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        2. Canada
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
  6. Europe Lung Cancer Genomic Testing Medicine Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
      6. By Country
        1. Germany
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        2. UK
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        3. Italy
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        4. France
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        5. Spain
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        6. The Netherlands
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        7. NORDIC Countries
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        8. Rest of Europe
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
  7. Asia Pacific Lung Cancer Genomic Testing Medicine Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
      6. By Country
        1. China
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        2. India
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        3. Japan
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        4. South Korea
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        5. Australia & New Zealand
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        6. Indonesia
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        7. Malaysia
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        8. Singapore
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        9. Philippines
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        10.  Vietnam
          1.  By Product Type
          2.  By Technology
          3.  By Sample Type
          4.  By Panel Type
          5.  By End-User
        11.  Rest of Asia Pacific
          1.  By Product Type
          2.  By Technology
          3.  By Sample Type
          4.  By Panel Type
          5.  By End-User
  8. Latin America Lung Cancer Genomic Testing Medicine Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
      6. By Country
        1. Brazil
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        2. Mexico
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        3. Argentina
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        4. Peru
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        5. Colombia
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        6. Rest of Latin America
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
  9.  Middle East & Africa Lung Cancer Genomic Testing Medicine Market
    1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
      6. By Country
        1. Saudi Arabia
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        2. UAE
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        3. Qatar
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        4. Kuwait
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        5. Iran
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        6. South Africa
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        7. Nigeria
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        8. Kenya
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        9. Egypt
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        10. Morocco
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        11. Algeria
          1. By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
        12. Rest of Middle East & Africa
          1.  By Product Type
          2. By Technology
          3. By Sample Type
          4. By Panel Type
          5. By End-User
  10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Lung Cancer Genomic Testing Medicine Company Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Merger, Acquisition, Partnership, and others)
  11. Impact of Covid-19 on Global Lung Cancer Genomic Testing Medicine System Market
  12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)
    1. QIAGEN
    2. Agilent Technologies, Inc.
    3. Thermo Fisher Scientific Inc.
    4. Quest Diagnostics Incorporated.
    5. Laboratory Corporation of America Holdings.
    6. CENTOGENE N.V.
    7. BGI
    8. CeGaT GmbH
    9. Illumina, Inc.
    10. F. Hoffmann-La Roche Ltd
    11. Others
  13. Key Strategic Recommendations
  14. Research Methodology
    1. Qualitative Research
      1. Primary & Secondary Research
    2. Quantitative Research
    3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
    4. Breakdown of Primary Research Respondents, By Region
    5. Assumption & Limitation

 

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List Of Figures

 

Figure 1              Global Lung Cancer Genomic Testing Medicine Market Segmentation

Figure 2              Global Lung Cancer Genomic Testing Medicine Market Value Chain Analysis

Figure 3              Company Market Share Analysis, 2021

Figure 4              Global Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 5       Global Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 6              Global Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 7       Global Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 8       Global Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 9              Global Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 10           Global Lung Cancer Genomic Testing Medicine Market Share, By Region, By Value, 2018-2028

Figure 11           North America Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 12           North America Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 13           North America Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 14     North America Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 15       North America Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 16           North America Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 17           North America Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 18           US Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 19         US Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 20            US Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 21              US Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 22            US Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 23           US Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 24              Canada Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 25      Canada Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 26           Canada Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 27              Canada Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 28             Canada Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 28            Canada Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 30           Europe Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 31           Europe Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 32           Europe Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 33     Europe Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 34      Europe Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 35           Europe Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 36           Europe Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 37           Germany Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 38 Germany Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 39        Germany Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 40           Germanys Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 41            Germany Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 42           Germany Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 43           UK Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 44         UK Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 45            UK Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 46            UK Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 47            UK Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 48            UK Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 49              Italy Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 50         Italy Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 51              Italy Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 52            Italy Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 53            Italy Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 54           Italy Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 55            France Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 56          France Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 57              France Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 58             France Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 59           France Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 60            France Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 61            Spain Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 62         Spain Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 63          Spain Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 64            Spain Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 65           Spain Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 66           Spain Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 67             The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 68        The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 69            The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 70            The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 71            The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 72            The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 73            NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 74        NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 75            NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 76            NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 77            NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 78            NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 79              Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 80         Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 81            Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 82            Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 83            Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 84           Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 85           The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 86           The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 87           The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 88    The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 89      The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 90           The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 91           The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 92            China Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 93         China Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 94          China Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 95             China Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 96           China Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 97           China Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 98            India Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 99       India Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 100            India Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 101             India Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 102         India Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 103         India Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 104              Japan Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 105      Japan Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 106          Japan Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 107              Japan Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 108         Japan Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 109         Japan Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 110          South Korea Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 111        South Korea Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 112           South Korea Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 113           South Korea Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 114         South Korea Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 115          South Korea Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 116         Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 117      Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 118         Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 119         Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 120         Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 121         Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 122           Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 123        Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 124          Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 125         Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 126          Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 127           Indonesia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 128         Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 129     Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 130   Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure   131           Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 132          Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 133         Malaysia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 134          Singapore  Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 135        Singapore Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 136           Singapore Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 137         Singapore Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 138          Singapore Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 139           Singapore Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 140             Philippines Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 141     Philippines Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 142      Philippines Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 143        Philippines Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 144          Philippines Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 145           Philippines Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 146         Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 147     Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 148         Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 149        Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 150          Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 151        Vietnam Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 152         Latin America Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 153         Latin America Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 154         Latin America Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 155  Latin America Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 156 Latin America Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 157         Latin America Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 158         Latin America Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 159         Brazil Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 160   Brazil Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 161        Brazil Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 162        Brazil Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 163             Brazil Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 164            Brazil Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 165         Mexico Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 166     Mexico Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 167       Mexico Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 168          Mexico Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 169        Mexico Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 170         Mexico Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 171           Argentina Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 172    Argentina Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 173           Argentina Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 174         Argentina Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 175          Argentina Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 176        Argentina Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 177           Peru Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 178    Peru Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 179         Peru Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 180         Peru Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 181          Peru Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 182         Peru Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 183             Colombia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 184       Colombia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 185            Colombia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 186            Colombia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 187              Colombia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 188           Colombia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 189            Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 190       Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 191           Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 192             Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 193             Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 194              Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 195         The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 196         The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 197         The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 198   The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 199    The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 200         The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 201         The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 202            Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 203       Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 204            Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 205             Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 206             Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 207             Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 208              UAE Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 209      UAE Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 210            UAE Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 211              UAE Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 212             UAE Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 213           UAE Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 214             Qatar Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 215    Qatar Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 216        Qatar Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 217              Qatar Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 218           Qatar Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 219         Qatar Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 220          Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 221   Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 222            Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 223             Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 224            Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 225             Kuwait Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 226           Iran Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 227      Iran Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 228             Iran Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 229              Iran Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 230              Iran Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 231             Iran Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 232             South Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 233    South Africa Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 234          South Africa Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 235           South Africa Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 236             South Africa Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 237          South Africa Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 238              Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 239       Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 240        Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 241           Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 242             Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 243             Nigeria Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 244             Kenya Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 245       Kenya Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 246             Kenya Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 247              Kenya Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 248             Kenya Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 249             Kenya Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 250              Egypt Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 251      Egypt Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 252        Egypt Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 253           Egypt Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 254         Egypt Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 255         Egypt Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 266         Morocco Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 267     Morocco Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 268           Morocco Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 269         Morocco Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 270           Morocco Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 271         Morocco Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 272          Algeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 273   Algeria Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 274        Algeria Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 275           Algeria Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 276         Algeria Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 277          Algeria Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 278          Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 279     Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 280         Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 281          Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 282          Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 283          Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

List Of Tables

Table 1 Global Lung Cancer Genomic Testing Medicine Market Size, By Product Type, By

Value, 2018-2028

Table 2 Global Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 3 Global Lung Cancer Genomic Testing Medicine Market Size, By Sample,

By Value, 2018-2028

Table 4 Global Lung Cancer Genomic Testing Medicine Market Size, By Panel,

By Value, 2018-2028

Table 5 Global Lung Cancer Genomic Testing Medicine Market Size, By End User, By

Value, 2018-2028

Table 6 Global Lung Cancer Genomic Testing Medicine Market Size, By Region, By

Value, 2018-2028

Table 7 North America Lung Cancer Genomic Testing Medicine Market Size, By Product

Type, By Value, 2018-2028

Table 8 North America Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 9 North America Lung Cancer Genomic Testing Medicine Market Size, By

Sample Type, By Value, 2018-2028

Table 10 North America Lung Cancer Genomic Testing Medicine Market Size, By

Panel Type, By Value, 2018-2028

Table 11 North America Lung Cancer Genomic Testing Medicine Market Size, By End User,

By Value, 2018-2028

Table 12 North America Lung Cancer Genomic Testing Medicine Market Size, By Country,

By Value, 2018-2028

Table 13 US Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 14 US Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 15 US Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 16 US Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 17 US Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 18 US Minimal Residual Disease (MRD) Testing Market Size, By End User,

By Value, 2018-2028

Table 19 Canada Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 20 Canada Minimal Residual Disease (MRD) Testing Market Share, By Product Type,

By Value, 2018-2028

Table 21 Canada Minimal Residual Disease (MRD) Testing Market Share, By Technology, By

Value, 2018-2028

Table 22 Canada Minimal Residual Disease (MRD) Testing Market Share, By Sample Type,

By Value, 2018-2028

Table 23 Canada Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By

Value, 2018-2028

Table 24 Canada Minimal Residual Disease (MRD) Testing Market Share, By End User, By

Value, 2018-2028

Table 25 Europe Lung Cancer Genomic Testing Medicine Market Size, By Product Type,

By Value, 2018-2028

Table 26 Europe Lung Cancer Genomic Testing Medicine Market Size, By Technology, By

Value, 2018-2028

Table 27 Europe Lung Cancer Genomic Testing Medicine Market Size, By Sample Type, By

Value, 2018-2028

Table 28 Europe Lung Cancer Genomic Testing Medicine Market Size, By Panel Type, By

Value, 2018-2028

Table 29 Europe Lung Cancer Genomic Testing Medicine Market Size, By End User, By

Value, 2018-2028

Table 30 Europe Lung Cancer Genomic Testing Medicine Market Size, By Country, By Value,

2018-2028

Table 31 Germany Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 32 Germany Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 33 Germany Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 34 Germanys Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 35 Germany Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 36 Germany Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 37 UK Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 38 UK Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 39 UK Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 40 UK Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 41 UK Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 42 UK Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 43 Italy Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million),

2018-2028

Table 44 Italy Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 45 Italy Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 46 Italy Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 47 Italy Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 48 Italy Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value,

2018-2028

Table 49 France Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 50 France Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 51 France Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 52 France Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 53 France Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 54 France Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 55 Spain Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 56 Spain Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 57 Spain Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 58 Spain Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 59 Spain Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 60 Spain Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value,

2018-2028

Table 61 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 62 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 63 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 64 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 65 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 66 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 67 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 68 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By

Product Type, By Value, 2018-2028

Table 69 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 70 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 71 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 72 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By End

User, By Value, 2018-2028

Table 73 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 74 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 75 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 76 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 77 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 78 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By End User,

By Value, 2018-2028

Table 79 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Product

Type, By Value, 2018-2028

Table 80 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 81 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Sample

Type, By Value, 2018-2028

Table 82 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Panel

Type, By Value, 2018-2028

Table 83 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By End User,

By Value, 2018-2028

Table 84 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Country,

By Value, 2018-2028

Table 85 China Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 86 China Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 87 China Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 88 China Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 89 China Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 90 China Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 91 India Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 92 India Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 93 India Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 94 India Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 95 India Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 96 India Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value,

2018-2028

Table 97 Japan Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 98 Japan Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 99 Japan Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 100 Japan Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 101 Japan Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 102 Japan Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 103 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 104 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 105 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 106 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 107 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 108 South Korea Minimal Residual Disease (MRD) Testing Market Size, By End User,

By Value, 2018-2028

Table 109 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 110 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 111 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 112 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 113 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 114 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 115 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 116 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 117 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Technology,

By Value, 2018-2028

Table 118 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 119 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type,

By Value, 2018-2028

Table 120 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 121 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 122 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 123 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 124 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 125 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 126 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 127 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 128 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 129 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Technology,

By Value, 2018-2028

Table 130 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 131 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Panel Type,

By Value, 2018-2028

Table 132 Singapore Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 133 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 134 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 135 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Technology,

By Value, 2018-2028

Table 136 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 137 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Panel Type,

By Value, 2018-2028

Table 138 Philippines Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 139 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 140 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 141 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 142 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 143 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 144 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 145 Latin America Lung Cancer Genomic Testing Medicine Market Size, By Product

Type, By Value, 2018-2028

Table 146 Latin America Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 147 Latin America Lung Cancer Genomic Testing Medicine Market Size, By Sample

Type, By Value, 2018-2028

Table 148 Latin America Lung Cancer Genomic Testing Medicine Market Size, By Panel

Type, By Value, 2018-2028

Table 149 Latin America Lung Cancer Genomic Testing Medicine Market Size, By End User,

By Value, 2018-2028

Table 149 Latin America Lung Cancer Genomic Testing Medicine Market Size, By

Country, By Value, 2018-2028

Table 150 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 151 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 152 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 153             Brazil Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 154        Brazil Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 155         Brazil Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 156          Mexico Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 157    Mexico Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 158         Mexico Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 159         Mexico Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 160          Mexico Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 161         Mexico Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 162         Argentina Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 163    Argentina Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 164             Argentina Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 165             Argentina Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 166         Argentina Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 167          Argentina Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 168           Peru Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 169    Peru Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 170         Peru Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 171          Peru Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 172         Peru Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 173             Peru Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 174              Colombia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 175      Colombia Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 176             Colombia Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 177              Colombia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 178              Colombia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 179              Colombia Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 180              Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 181       Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 182             Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 183              Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 184              Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 185             Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 186          The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Product Type, By Value, 2018-2028

Table 187          The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Technology, By Value, 2018-2028

Table 188         The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Sample Type, By Value, 2018-2028

Table 189        The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Panel Type, By Value, 2018-2028

Table 190          The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By End User, By Value, 2018-2028

Table 191          The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Country, By Value, 2018-2028

Table 192              Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 193       Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 194            Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 195              Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 196             Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 197              Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 198              UAE Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 199       UAE Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 200             UAE Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 201              UAE Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 202             UAE Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 203             UAE Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 204              Qatar Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 205       Qatar Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 206             Qatar Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 207              Qatar Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 208              Qatar Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 209             Qatar Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 210              Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 211       Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 212            Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 213              Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 214              Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 215             Kuwait Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 216            Iran Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 217       Iran Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 218             Iran Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 219            Iran Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 220              Iran Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 221              Iran Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 222              South Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 223       South Africa Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 224             South Africa Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 225             South Africa Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 226              South Africa Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 227              South Africa Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 228              Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 229       Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 230             Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 231             Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 232              Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 233             Nigeria Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 234              Kenya Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 235       Kenya Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 236             Kenya Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 237              Kenya Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 238              Kenya Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 239              Kenya Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 240              Egypt Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 241       Egypt Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 242             Egypt Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 243              Egypt Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 244              Egypt Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 245              Egypt Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 246              Morocco Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 247       Morocco Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 248             Morocco Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 249              Morocco Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 250              Morocco Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 251            Morocco Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 252              Algeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 253      Algeria Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 254            Algeria Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 255              Algeria Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 256              Algeria Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 257             Algeria Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 258              Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 259       Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 260             Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 261        Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 262              Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 263             Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 264          QIAGEN Company Overview

Table 265          QIAGEN Financial Overview

Table 266          AGILENT TECHNOLOGIES, INC.  Company Overview

Table 267          AGILENT TECHNOLOGIES, INC.  Financial Overview

Table 268          Thermo Fisher Scientific Inc. Company Overview

Table 269          Thermo Fisher Scientific Inc. Financial Overview

Table 270          QUEST DIAGNOSTICS INCORPORATED.  Company Overview

Table 271          QUEST DIAGNOSTICS INCORPORATED.  Financial Overview

Table 272          Laboratory Corporation of America Holdings. Company Overview

Table 273          Laboratory Corporation of America Holdings. Financial Overview

Table 274          CENTOGENE N.V. Company Overview

Table 275          CENTOGENE N.V. Financial Overview

Table 276          BGI Company Overview

Table 277          BGI Financial Overview

Table 278          CeGaT GmbH Company Overview

Table 279          CeGaT GmbH Financial Overview

Table 280          Illumina, Inc. Company Overview

Table 281          Illumina, Inc. Financial Overview

Table 282          F. HOFFMANN-LA ROCHE LTD Company Overview

Table 283          F. HOFFMANN-LA ROCHE LTD Financial Overview

Market Segmentation

By Product Type

  • Products

  • Services

By Technology

  • Polymerase Chain Reaction

  • Next-Generation Sequencing

  • Fluorescence In-Situ Hybridization

  • Others

By Sample Type

  • Tissue Biopsy

  • Liquid Biopsy

By Panel Type

  • Multi-Gene Panel

  • Single-Gene Panel

By End-User

  • Research Organization

  • Hospitals/Clinics

  • Diagnostic Laboratories

  • Others

By Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Note: Please share the corporate email address for faster response

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: The major factors driving the growth of the global lung cancer genomic testing medicine market is the rising number of cancer patients leading to recent launches of novel lung cancer genomic testing as well as expanding research into lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.
Ans: Global lung cancer genomic testing medicine market is expected to reach USD 4.27 billion by 2028.
Ans: The services segment accounted for the largest share in the global lung cancer genomic testing medicine market.
Ans: North America region has the largest share in global lung cancer genomic testing medicine market.
Ans: The key players in the global lung cancer genomic testing medicine market are QIAGEN, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, CENTOGENE N.V., BGI, CeGaT GmbH, Illumina Inc., F. Hoffmann-La Roche Ltd, and other prominent players.
array(1) {
  ["__ci_last_regenerate"]=>
  int(1733296163)
}